The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments.

AGREE cutaneous melanoma level of evidence melanoma treatment practice guideline

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 Jun 2020
Historique:
received: 02 04 2020
revised: 10 06 2020
accepted: 17 06 2020
entrez: 24 6 2020
pubmed: 24 6 2020
medline: 24 6 2020
Statut: epublish

Résumé

Multiple guidelines on cutaneous melanoma (CM) are available from several consortia and countries. To provide up-to-date guidance in the rapidly changing field of melanoma treatment, guideline developers have to provide regular updates without compromises of quality. We performed a systematic search in guideline databases, Medline and Embase to identify guidelines on CM. The methodological quality of the identified guidelines was independently assessed by five reviewers using the instruments "Appraisal of Guidelines for Research and Evaluation" (AGREE II) and "Recommendation EXcellence" (AGREE-REX). We performed descriptive analysis, explored subgroup differences using the Kruskal-Wallis (H) test and examined the relationship between distinct domains and items of the instruments with Spearman's correlation. Six guidelines by consortia from Australia, France, Germany, Scotland, Spain and the United States of America were included. The German guideline fulfilled 71%-98% of criteria in AGREE II and 78%-96% for AGREE-REX, obtaining the highest scores. Deficiencies in the domains of "applicability" and "values and preferences" were observed in all guidelines. The German and Spanish guidelines significantly differed from each other in most of the domains. The domains "applicability" and "values and preferences" were identified as methodological weaknesses requiring careful revision and improvement in the future.

Identifiants

pubmed: 32570843
pii: cancers12061613
doi: 10.3390/cancers12061613
pmc: PMC7352745
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Cancer. 2020 Feb;126:141-158
pubmed: 31928887
An Bras Dermatol. 2016 Jan-Feb;91(1):49-58
pubmed: 26982779
BMJ. 2015 Jul 29;351:h3708
pubmed: 26223435
Clin Transl Oncol. 2018 Jan;20(1):69-74
pubmed: 29116432
Eur J Cancer. 2020 Jan;125:114-120
pubmed: 31864178
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402
pubmed: 30959471
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Eur J Cancer. 2020 Feb;126:33-44
pubmed: 31901705
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
J Evid Based Med. 2015 Feb;8(1):2-10
pubmed: 25594108
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):594-602
pubmed: 28120528
Eur J Dermatol. 2015 Sep-Oct;25(5):392-403
pubmed: 26693633
Chin Clin Oncol. 2016 Aug;5(4):57
pubmed: 27164849
Semin Nucl Med. 2019 Mar;49(2):145-152
pubmed: 30819394
Int J Qual Health Care. 2005 Jun;17(3):235-42
pubmed: 15743883
J R Coll Physicians Edinb. 2017 Sep;47(3):214-217
pubmed: 29465095
Open Med. 2009;3(3):e123-30
pubmed: 21603045
J Natl Compr Canc Netw. 2018 May;16(5S):646-650
pubmed: 29784747
J Eur Acad Dermatol Venereol. 2019 Dec;33 Suppl 8:25-32
pubmed: 31833609
Eur J Cancer. 2020 Feb;126:159-177
pubmed: 31866016
Kidney Int. 2016 Apr;89(4):753-60
pubmed: 26994574
Artif Intell Med. 2009 May;46(1):55-66
pubmed: 18950994
J Am Acad Dermatol. 2019 Jan;80(1):208-250
pubmed: 30392755
Ann Oncol. 2015 Sep;26 Suppl 5:v126-32
pubmed: 26314774
Eur J Cancer. 2016 Aug;63:201-17
pubmed: 27367293
Rev Esp Salud Publica. 2004 Jul-Aug;78(4):457-67
pubmed: 15384260
J Clin Med. 2019 Mar 15;8(3):
pubmed: 30884760
J Cancer Res Clin Oncol. 2020 Apr;146(4):1079-1088
pubmed: 32036455
An Bras Dermatol. 2015 Nov-Dec;90(6):851-61
pubmed: 26734867
J Clin Epidemiol. 2010 Dec;63(12):1281-2
pubmed: 20605571

Auteurs

Theresa Steeb (T)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Anja Wessely (A)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Konstantin Drexler (K)

Department of Dermatology, University Hospital Regensburg, 93053 Regensburg, Germany.

Martin Salzmann (M)

Department of Dermatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Frédéric Toussaint (F)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Lucie Heinzerling (L)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Markus Reinholz (M)

Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian University, 80337 Munich, Germany.

Carola Berking (C)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Markus V Heppt (MV)

Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nürnberg (CCC ER-EMN), 91054 Erlangen, Germany.

Classifications MeSH